NCT03932279 Characterization of the Microbiome in Cutaneous T Cell Lymphoma
| NCT ID | NCT03932279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Cutaneous T Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2019-01-30 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2019-01-30 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
Eligibility Criteria
Inclusion Criteria: * Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma * Group 2: Patients with stage IIB and above cutaneous T cell lymphoma * Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma * Group 4: Patients with plaque psoriasis with BSA\>5% on routine phototherapy per standard of care * Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care * Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma * All Groups: subjects who are age 18-89 years of age at time of enrollment * All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443). Exclusion Criteria: * All Groups: Subjects who are younger than 18 years of age or older than 90 years of age * All Groups: Subjects who are unable to give consent * Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics * We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
Contact & Investigator
Alan Zhou, MD
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT03932279 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Cutaneous T Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03932279 currently recruiting?
Yes, NCT03932279 is actively recruiting participants. Contact the research team at NUderm-research@northwestern.edu for enrollment information.
Where is the NCT03932279 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT03932279 clinical trial?
NCT03932279 is sponsored by Northwestern University. The principal investigator is Alan Zhou, MD at Northwestern University. The trial plans to enroll 300 participants.